Clinical trials: Hepatitis, Viral, Human
Hepatitis C Virus
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691
To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.
- Trial name
- NCT00810758
- Testing
- PF-04878691 3mg, PF-04878691 6mg, PF-04878691 9mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Hepatitis B
Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal…
- Trial name
- NCT00869778
- Testing
- εPA-44
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Hepatitis B, Tenofovir
Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B.
Hepatitis B virus (HBV) can be asymptomatic for years but can also lead to chronic hepatitis, hepatocellular carcinoma, and liver failure and death and cannot be eradicated with the current therapy.
- Conditions
- Hepatitis B, Tenofovir, Pregnancy
- Trial name
- PK-TDF (NCT04114890)
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- University of Oxford
Hepatitis C
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
To provide access to a telaprevir-based treatment to subjects of the Control Group of Study VX06-950-106 (NCT00420784), VX05-950-104 (NCT00336479), and VX05-950-104EU (NCT00372385) who stopped treatment due to inadequate response…
- Trial name
- NCT00535847
- Testing
- Telaprevir, Ribavirin, Pegylated interferon alfa 2a
- Where
- 62 sites in United States, Austria and 6 more
- Volunteers
- 117 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic
The purpose of this study is to learn more about what psychological and social factors affect people in how they take their hepatitis C medications.
- Trial name
- NCT03831555
- Testing
- PREP-C
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Emory University
Chronic Hepatitis B Virus
T-cell Dysfunction in Chronic HBV Infection
Chronic hepatitis B (CHB) infection remains an important public health with more than 240 million people chronically infected despite the existence of an effective vaccine.
- Trial name
- VHB-Roche (NCT05099458)
- Testing
- Additional blood sampling (100 ml)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Chronic Hepatitis b, Hepatic Carcinoma
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
The current study is a prospective, randomized, open, multi-center investigation. The aim of current study is to investigate whether the Recurrence-free Survival Rate (RFS）of the hepatitis B related -hepatocellular carcinoma…
- Trial name
- NCT03253250
- Testing
- ETV；TDF；ADV, Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Huashan Hospital
Hepatitis B, Hemodialysis Complication
Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients
The aim of this study is to examine the result of seroprotection using the accelerated vaccination schedule in vaccination of hemodialysis patient through using combined hepatitis A and B vaccine.
- Trial name
- NCT03149874
- Testing
- Hepatitis B recombinant DNA vaccine, Combined hepatitis A and B vaccine
- Volunteers
- 114 people
- Sponsor
- Benha University
Hepatitis C, Chronic
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
The substances BI 201335 and BI 207127 are being developed for the treatment of chronic hepatitis C virus infection. BI 201335 and BI 207127 work by preventing the virus from replicating.
- Trial name
- NCT01132313
- Testing
- BI 207127, BI 201335, Ribavirin
- Where
- 53 sites in United States, Australia and 8 more
- Volunteers
- 488 people
- Sponsor
- Boehringer Ingelheim
Hepatitis B, Hepatitis D
Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Background: Sudan has a high prevalence of hepatitis B surface antigen (HBsAg), exceeding 8%. The prevalence of hepatitis B varies across different regions of Sudan, ranging from 6.8% in central Sudan to as high as 26% in…
- Conditions
- Hepatitis B, Hepatitis D, Viral Hepatitis
- Trial name
- NCT06360484
- Testing
- investigations for Hepatitis D virus
- Where
- Sudan
- Volunteers
- 90 people
- Sponsor
- National Center for Gastroentestinal and Liver Disease
Viral Hepatitis
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
- Trial name
- NCT06903338
- Testing
- Tobevibart, Elebsiran
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 124 people
- Sponsor
- Vir Biotechnology, Inc.
Healthy, Hepatitis C
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
The purpose of this study is to determine the rate of kidney or heart impairment, if any, in subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials
- Trial name
- NCT01732848
- Testing
- BMS-986094/INX-08189
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Complication of Transplanted Liver, Hepatitis C, Chronic
Prediction of Hepatitis C Recurrence in Liver Transplant Recipients
The purpose of the study is to look at cells of the immune system to see if the cells are different among people with different risk factors that have received a liver transplant.
- Trial name
- NCT00867243
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwestern University
HIV Infections, Hepatitis C
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in HIV/HCV coinfected…
- Trial name
- NCT00437684
- Testing
- LPV/r, PEG-IFNa 2a, Ribavirin
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Chronic Hepatitis B
The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia
Chronic hepatitis B seriously endangers the health of our people, especially the occurrence of HCC, which brings huge economic burden and life threat to our people. 84% - 92% of HCC in China is related to chronic HBV infection.
- Trial name
- NCT05357235
- Testing
- PEG-IFN
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.
- Trial name
- NCT02738008
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 6 sites in China, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis C, Chronic
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with hepatitis C, genotype 4.
- Trial name
- ELEGANT-4 (NCT03578640)
- Testing
- Elbasvir, Grazoprevir 50-100Mg Oral Tablet
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Fahad Medical City
Hepatitis B
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
Persistence of anti-HBs antibodies at Month 24, 30 and 36 in subjects who had completed primary vaccination was evaluated. The anamnestic response to a booster dose was evaluated in subjects with anti-HBs antibody titres < 10…
- Trial name
- NCT00383591
- Testing
- Hepatitis B adjuvanted vaccine, Engerix-B
- Where
- 5 sites in Czechia, Malaysia and 1 more
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
HIV, Sickle Cell Disease
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
The investigators propose to adopt sustainable community networks (in this case churches) to implement an integrated community-based screening that incorporates mobile health technology (mHealth) to make prenatal test results…
- Conditions
- HIV, Sickle Cell Disease, Hepatitis B
- Trial name
- mHealth (NCT03027258)
- Testing
- mHealth
- Where
- Nigeria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Nevada, Las Vegas
Hepatitis D, Chronic
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Open label, single arm, multi-center clinical trial of lonafarnib 50 mg QD plus ritonavir 200 mg QD, administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic…
- Trial name
- LOWR6 (NCT05229991)
- Testing
- Lonafarnib, Ritonavir
- Where
- 3 sites in Israel, New Zealand and 1 more
- Volunteers
- 10 people
- Sponsor
- Soroka University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.